Literature DB >> 7492164

Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis.

G S Dick1, S T Meller, C R Pinkerton.   

Abstract

The serotonin (5HT3) antagonist ondansetron was compared in a randomised study with metoclopramide and dexamethasone for the prevention of chemotherapy induced emesis. Thirty children aged 1-15 years with acute lymphoblastic leukaemia received 'intensification modules' according to the MRC United Kingdom acute lymphoblastic leukaemia regimen UKALL XI. This contains the moderately emetogenic drugs daunorubicin, etoposide, and cytarabine. Fifteen children received an intravenous loading dose of ondansetron followed by intravenous or oral doses 12 hourly for five days. Fifteen children received intravenous metoclopramide every six hours for three days with a loading dose of dexamethasone, repeated every eight hours for three days intravenously or orally. Efficacy was assessed by a diary card documenting the incidence of nausea, retching, or vomiting. In the 24 hour period after starting chemotherapy, ondansetron was more effective, with a complete or major response rate of 93%, compared with 33% using metoclopramide/dexamethasone.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7492164      PMCID: PMC1511304          DOI: 10.1136/adc.73.3.243

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  13 in total

1.  GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting.

Authors:  M Marty; J P Droz; P Pouillart; B Paule; N Brion; J Bons
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Ondansetron with and without dexamethasone to treat chemotherapy-induced emesis.

Authors:  D Cunningham; A Turner; J Hawthorn; R D Rosin
Journal:  Lancet       Date:  1989-06-10       Impact factor: 79.321

3.  Chemotherapy-associated nausea and vomiting in pediatric oncology patients.

Authors:  S B Frick; E Guzzi DelPo; J A Keith; M S Davis
Journal:  Cancer Nurs       Date:  1988-04       Impact factor: 2.592

4.  Side effects of metoclopramide as an antiemetic in childhood cancer chemotherapy.

Authors:  B N Terrin; N B McWilliams; H M Maurer
Journal:  J Pediatr       Date:  1984-01       Impact factor: 4.406

5.  5-HT3 antagonist ondansetron--an effective outpatient antiemetic in cancer treatment.

Authors:  C R Pinkerton; D Williams; C Wootton; S T Meller; T J McElwain
Journal:  Arch Dis Child       Date:  1990-08       Impact factor: 3.791

6.  On the receiving end--patient perception of the side-effects of cancer chemotherapy.

Authors:  A Coates; S Abraham; S B Kaye; T Sowerbutts; C Frewin; R M Fox; M H Tattersall
Journal:  Eur J Cancer Clin Oncol       Date:  1983-02

7.  Extrapyramidal reactions with metoclopramide.

Authors:  D N Bateman; M D Rawlins; J M Simpson
Journal:  Br Med J (Clin Res Ed)       Date:  1985-10-05

8.  A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues.

Authors:  D Cunningham; C J Bradley; G J Forrest; A W Hutcheon; L Adams; M Sneddon; M Harding; D J Kerr; M Soukop; S B Kaye
Journal:  Eur J Cancer Clin Oncol       Date:  1988-04

9.  Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy.

Authors:  J C Allen; R Gralla; L Reilly; M Kellick; C Young
Journal:  J Clin Oncol       Date:  1985-08       Impact factor: 44.544

10.  Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.

Authors:  R J Gralla; L M Itri; S E Pisko; A E Squillante; D P Kelsen; D W Braun; L A Bordin; T J Braun; C W Young
Journal:  N Engl J Med       Date:  1981-10-15       Impact factor: 91.245

View more
  8 in total

Review 1.  Ondansetron: a review of its use as an antiemetic in children.

Authors:  C R Culy; N Bhana; G L Plosker
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 2.  Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice.

Authors:  E S Antonarakis; R D W Hain
Journal:  Arch Dis Child       Date:  2004-09       Impact factor: 3.791

3.  2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children.

Authors:  L Lee Dupuis; Lillian Sung; Alexander Molassiotis; Andrea D Orsey; Wim Tissing; Marianne van de Wetering
Journal:  Support Care Cancer       Date:  2016-08-26       Impact factor: 3.603

Review 4.  Acute gastroenteritis in children: role of anti-emetic medication for gastroenteritis-related vomiting.

Authors:  Alexander K C Leung; Wm Lane M Robson
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 5.  The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis.

Authors:  Melissa Lau Moon Lin; Paula D Robinson; Jacqueline Flank; Lillian Sung; L Lee Dupuis
Journal:  Drug Saf       Date:  2016-07       Impact factor: 5.606

Review 6.  Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children.

Authors:  L Lee Dupuis; Paul C Nathan
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 7.  Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood.

Authors:  Robert S Phillips; Amanda J Friend; Faith Gibson; Elizabeth Houghton; Shireen Gopaul; Jean V Craig; Barry Pizer
Journal:  Cochrane Database Syst Rev       Date:  2016-02-02

8.  An overview of the clinical use of ondansetron in preschool age children.

Authors:  Ira Todd Cohen
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.